Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi: Arguably One Of The Most Undervalued Pharma Stocks
01:31am, Friday, 29'th Jul 2022
I am bullish on Sanofi as I see the company undervalued as compared to both the company's financials and competitors (EU pharma peers). Sanofi is a leading global pharmaceutical company, with strong r
Sanofi SA (SNY) CEO Paul Hudson on Q2 2022 Results - Earnings Call Transcript
01:24pm, Thursday, 28'th Jul 2022
Sanofi SA (NASDAQ:SNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Jean-Baptiste de Chatillon - EVP & CFO Bill Sibo
Sanofi lifts profit outlook as Dupixent sales surge over 43%
01:33am, Thursday, 28'th Jul 2022
French healthcare group Sanofi lifted its full-year earnings outlook on continued strong sales growth for its bestselling drug Dupixent.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
12:24pm, Thursday, 14'th Jul 2022
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
Is Sanofi on the Verge of Another Blockbuster?
11:00am, Saturday, 09'th Jul 2022
Sanofi and Regeneron's Dupixent could be months away from regulatory approval for another skin condition in the U.S.
C4X Discovery nets €3mln Sanofi milestone payment
03:25am, Wednesday, 06'th Jul 2022
Drug developer C4X Discovery Holdings PLC (AIM:C4XD) has hit the first milestone in a licensing deal with Sanofi after progressing pre-clinical trials for an immunotherapy drug. The company is dev
3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks
11:43am, Tuesday, 05'th Jul 2022
Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
03:45pm, Friday, 01'st Jul 2022 Zacks Investment Research
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
01:52pm, Friday, 01'st Jul 2022
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
3 Stocks With Solid Records of Sales and Earnings Growth
11:58am, Friday, 01'st Jul 2022
Investors may want to consider the stocks in this article, in my view, since they meet the following value criteria:
Why This Company Could See Long-Lasting Tailwinds Despite the Bear Market
11:47am, Friday, 01'st Jul 2022 The Motley Fool
An industry-leading company looks past COVID-19 to future growth.
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
10:57am, Friday, 01'st Jul 2022 Zacks Investment Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
09:26am, Friday, 01'st Jul 2022 Benzinga
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Only one n
5 Top Biotech Stocks To Watch In July 2022
02:30pm, Thursday, 30'th Jun 2022
Amid choppy markets, could there be potential in these top biotech stocks?
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
12:56pm, Thursday, 30'th Jun 2022 Zacks Investment Research
FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.
